- Home
- THRD vs NGNE Comparison
THRD vs NGNE Comparison
Compare THRD & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- NGNE
- Stock Information
- Founded
- THRD 2019
- NGNE 2003
- Country
- THRD United States
- NGNE United States
- Employees
- THRD N/A
- NGNE N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- THRD Health Care
- NGNE Health Care
- Exchange
- THRD Nasdaq
- NGNE Nasdaq
- Market Cap
- THRD 238.7M
- NGNE 213.2M
- IPO Year
- THRD 2022
- NGNE N/A
- Fundamental
- Price
- THRD $5.46
- NGNE $21.94
- Analyst Decision
- THRD Hold
- NGNE Strong Buy
- Analyst Count
- THRD 3
- NGNE 7
- Target Price
- THRD $5.00
- NGNE $41.86
- AVG Volume (30 Days)
- THRD 220.4K
- NGNE 225.4K
- Earning Date
- THRD 08-07-2025
- NGNE 08-08-2025
- Dividend Yield
- THRD N/A
- NGNE N/A
- EPS Growth
- THRD N/A
- NGNE N/A
- EPS
- THRD N/A
- NGNE N/A
- Revenue
- THRD N/A
- NGNE $925,000.00
- Revenue This Year
- THRD N/A
- NGNE N/A
- Revenue Next Year
- THRD N/A
- NGNE N/A
- P/E Ratio
- THRD N/A
- NGNE N/A
- Revenue Growth
- THRD N/A
- NGNE N/A
- 52 Week Low
- THRD $3.18
- NGNE $6.88
- 52 Week High
- THRD $16.02
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- THRD 66.73
- NGNE 62.83
- Support Level
- THRD $5.42
- NGNE $19.01
- Resistance Level
- THRD $5.45
- NGNE $18.21
- Average True Range (ATR)
- THRD 0.04
- NGNE 1.65
- MACD
- THRD -0.01
- NGNE 0.41
- Stochastic Oscillator
- THRD 50.00
- NGNE 96.68
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.